Senti Biosciences Inc Cash Flow Conversion Efficiency
Senti Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Senti Biosciences Inc (SNTI) has a cash flow conversion efficiency ratio of -1.163x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.45 Million) by net assets ($8.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Senti Biosciences Inc (2019–2024)
Cash flow conversion efficiency of Senti Biosciences Inc from 2019 to 2024. This chart illustrates how Senti Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Senti Biosciences Inc share price for real-time trading data and today's change.
Senti Biosciences Inc Cash Flow Conversion Ratio Explained
Senti Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Senti Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Senti Biosciences Inc ranked by their cash flow conversion efficiency. Also see SNTI company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asia Pacific Fibers Tbk
JK:POLY
|
-0.005x |
|
Citatah Tbk
JK:CTTH
|
-0.063x |
|
MAST ENERGY DEV. LS -001
F:97D
|
N/A |
|
Braster S.A.
WAR:BRA
|
-0.048x |
|
Trajano Iberia Socimi SA
MC:YTRA
|
0.005x |
|
CaliberCos Inc. Class A Common Stock
NASDAQ:CWD
|
-0.076x |
|
GB Group plc
LSE:GBG
|
0.047x |
|
Exact Therapeutics AS
OL:EXTX
|
-0.697x |
Annual Cash Flow Conversion Efficiency for Senti Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Senti Biosciences Inc from 2019 to 2024. Review how financially flexible is Senti Biosciences Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $25.65 Million | $-41.40 Million | -1.614x | -106.12% |
| 2023-12-31 | $66.91 Million | $-52.40 Million | -0.783x | -185.57% |
| 2022-12-31 | $127.26 Million | $-34.90 Million | -0.274x | +52.20% |
| 2021-12-31 | $60.38 Million | $-34.63 Million | -0.574x | -239.33% |
| 2020-12-31 | $-58.71 Million | $-24.17 Million | 0.412x | +140.25% |
| 2019-12-31 | $17.96 Million | $-18.38 Million | -1.023x | -- |
About Senti Biosciences Inc
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications w… Read more